Sign in or create an account to add this stock to your watchlist.
About Antares Pharma (NASDAQ:ATRS)
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020
Debt
Debt-to-Equity Ratio0.88
Current Ratio2.94
Quick Ratio2.39
Price-To-Earnings
Trailing P/E Ratio-23.00
Forward P/E Ratio-31.63
P/E GrowthN/A
Sales & Book Value
Annual Sales$54.51 million
Price / Sales7.28
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book12.05
Profitability
EPS (Most Recent Fiscal Year)($0.11)
Net Income$-16,740,000.00
Net Margins-32.96%
Return on Equity-52.74%
Return on Assets-23.67%
Miscellaneous
Employees111
Outstanding Shares156,830,000
Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions
What is Antares Pharma's stock symbol?
Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."
How were Antares Pharma's earnings last quarter?
Antares Pharma Inc (NASDAQ:ATRS) released its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The specialty pharmaceutical company had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.85 million. Antares Pharma had a negative net margin of 32.96% and a negative return on equity of 52.74%. View Antares Pharma's Earnings History.
What price target have analysts set for ATRS?
3 brokerages have issued 12-month price targets for Antares Pharma's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Antares Pharma's share price to reach $4.00 in the next year. View Analyst Ratings for Antares Pharma.
Who are some of Antares Pharma's key competitors?
Some companies that are related to Antares Pharma include Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), CryoLife (CRY), K2M Group (KTWO), Cerus (CERS), AtriCure (ATRC), Tactile Systems Technology (TCMD), MiMedx Group (MDXG) and AngioDynamics (ANGO).
Who are Antares Pharma's key executives?
Antares Pharma's management team includes the folowing people:
- Mr. Robert F. Apple, Chief Exec. Officer, Pres and Director (Age 52)
- Mr. Fred M. Powell CPA, Exec. VP & CFO (Age 57)
- Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. and Corp. Controller (Age 55)
- Mr. Peter J. Graham Esq., Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)
- Edward Kessig, VP of Sales
Has Antares Pharma been receiving favorable news coverage?
News stories about ATRS stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a media sentiment score of 0.08 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 46.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Antares Pharma's major shareholders?
Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.83%), Wells Fargo & Company MN (1.23%), JW Asset Management LLC (1.13%), Russell Investments Group Ltd. (0.57%), Schwab Charles Investment Management Inc. (0.45%) and Guggenheim Capital LLC (0.34%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.
Which major investors are selling Antares Pharma stock?
ATRS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JW Asset Management LLC, Guggenheim Capital LLC and A.R.T. Advisors LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.
Which major investors are buying Antares Pharma stock?
ATRS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., Wells Fargo & Company MN, Schwab Charles Investment Management Inc. and MetLife Investment Advisors LLC. View Insider Buying and Selling for Antares Pharma.
How do I buy shares of Antares Pharma?
Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Antares Pharma's stock price today?
One share of ATRS stock can currently be purchased for approximately $2.53.
How big of a company is Antares Pharma?
Antares Pharma has a market capitalization of $395.20 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.
How can I contact Antares Pharma?
Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]
MarketBeat Community Rating for Antares Pharma (ATRS)
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Antares Pharma (NASDAQ:ATRS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Antares Pharma in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 58.10%. The high price target for ATRS is $5.00 and the low price target for ATRS is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.25 | 3.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $4.0750 | $3.95 |
| Price Target Upside: | 58.10% upside | 81.82% upside | 105.81% upside | 138.67% upside |
Antares Pharma (NASDAQ:ATRS) Consensus Price Target History
Antares Pharma (NASDAQ:ATRS) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Antares Pharma (NASDAQ:ATRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Antares Pharma (NASDAQ ATRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 37.06%
Antares Pharma (NASDAQ ATRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2018 | Jacques Gonella | Director | Sell | 200,000 | $2.54 | $508,000.00 | 11,286,413 |  |
| 5/15/2018 | Jacques Gonella | Director | Sell | 200,000 | $2.50 | $500,000.00 | 11,486,413 | |
| 5/11/2018 | Jacques Gonella | Director | Sell | 200,000 | $2.42 | $484,000.00 | 11,686,413 | |
| 5/9/2018 | Jacques Gonella | Director | Sell | 300,000 | $2.47 | $741,000.00 | 11,936,413 | |
| 10/9/2017 | Leonard S Jacob | Director | Sell | 230,000 | $4.05 | $931,500.00 | | |
| 10/3/2017 | Thomas J Garrity | Director | Sell | 30,000 | $3.50 | $105,000.00 | | |
| 6/9/2017 | Fred M Powell | Insider | Buy | 130,000 | $2.79 | $362,700.00 | 331,434 | |
| 4/5/2017 | Robert F Apple | CEO | Sell | 40,000 | $3.00 | $120,000.00 | 927,002 | |
| 4/4/2017 | Leonard S Jacob | Director | Sell | 41,762 | $2.89 | $120,692.18 | 238,885 | |
| 4/4/2017 | Robert F Apple | CEO | Sell | 37,000 | $3.00 | $111,000.00 | 927,002 | |
| 4/3/2017 | Leonard S Jacob | Director | Sell | 20,000 | $2.88 | $57,600.00 | 238,885 | |
| 3/31/2017 | Thomas J Garrity | Director | Sell | 30,000 | $2.91 | $87,300.00 | 190,213 | |
| 12/9/2016 | Fred M Powell | Insider | Buy | 100,000 | $2.03 | $203,000.00 | 100,000 | |
| 3/21/2016 | Peter J Graham | SVP | Buy | 20,000 | $0.77 | $15,400.00 | 20,000 | |
| 3/18/2016 | James E Fickenscher | CFO | Buy | 135,000 | $0.72 | $97,200.00 | 270,216 | |
| 3/18/2016 | Leonard S Jacob | Director | Buy | 50,000 | $0.72 | $36,000.00 | 218,885 | |
| 3/18/2016 | Robert F Apple | CEO | Buy | 60,000 | $0.72 | $43,200.00 | 517,164 | |
| 9/30/2015 | James E Flynn | Major Shareholder | Sell | 249,998 | $1.69 | $422,496.62 | | |
| 9/29/2015 | James E Flynn | Major Shareholder | Sell | 225,048 | $1.82 | $409,587.36 | | |
| 9/28/2015 | James E Flynn | Major Shareholder | Sell | 1,353,483 | $1.81 | $2,449,804.23 | | |
| 8/24/2015 | Robert P Roche Jr | Director | Buy | 5,000 | $1.77 | $8,850.00 | 38,172 | |
| 8/13/2015 | Robert P Roche Jr | Director | Buy | 5,000 | $1.94 | $9,700.00 | | |
| 7/20/2015 | James E Flynn | Insider | Sell | 231,793 | $2.17 | $502,990.81 | | |
| 7/8/2015 | James E Flynn | Major Shareholder | Sell | 444,341 | $2.05 | $910,899.05 | | |
| 7/7/2015 | James E Flynn | Major Shareholder | Sell | 198,651 | $2.09 | $415,180.59 | | |
| 7/6/2015 | James E Flynn | Major Shareholder | Sell | 191,513 | $2.12 | $406,007.56 | | |
| 7/1/2015 | James E Flynn | Insider | Sell | 713,222 | $2.09 | $1,490,633.98 | | |
| 6/30/2015 | James E Flynn | Major Shareholder | Sell | 608,691 | $2.08 | $1,266,077.28 | | |
| 6/29/2015 | James E Flynn | Major Shareholder | Sell | 60,695 | $2.18 | $132,315.10 | | |
| 6/26/2015 | James E Flynn | Insider | Sell | 756,852 | $2.27 | $1,718,054.04 | | |
| 6/23/2015 | James E Flynn | Insider | Sell | 499,895 | $2.39 | $1,194,749.05 | | |
| 6/18/2015 | James E Flynn | Insider | Sell | 478,366 | $2.44 | $1,167,213.04 | | |
| 6/15/2015 | James E Flynn | Insider | Sell | 748,030 | $2.44 | $1,825,193.20 | | |
| 3/23/2015 | Leonard S Jacob | Director | Sell | 23,500 | $2.68 | $62,980.00 | | |
| 9/10/2014 | Eamonn P Hobbs | CEO | Buy | 9,000 | $2.20 | $19,800.00 | | |
| 8/13/2014 | Robert P Roche Jr | Director | Buy | 5,000 | $1.96 | $9,800.00 | | |
| 8/11/2014 | Marvin Samson | Director | Buy | 25,000 | $2.00 | $50,000.00 | | |
| 12/9/2013 | Paul Wotton | CEO | Sell | 64,100 | $4.00 | $256,400.00 | 708,734 | |
| 10/14/2013 | Robert Apple | CFO | Sell | 22,000 | $5.05 | $111,100.00 | 368,918 | |
| 9/3/2013 | Anton Gueth | Director | Sell | 25,000 | $4.42 | $110,500.00 | 245,976 | |
| 9/3/2013 | Paul Wotton | CEO | Sell | 35,000 | $4.41 | $154,350.00 | 708,734 | |
| 8/1/2013 | Anton Gueth | Director | Sell | 25,000 | $4.41 | $110,250.00 | | |
| 8/1/2013 | Paul K Wotton | CEO | Sell | 35,000 | $4.42 | $154,700.00 | | |
| 7/1/2013 | Anton Gueth | Director | Sell | 25,000 | $4.15 | $103,750.00 | | |
| 7/1/2013 | Paul K Wotton | CEO | Sell | 35,000 | $4.14 | $144,900.00 | | |
| 6/25/2013 | Eamonn P Hobbs | Director | Sell | 23,500 | $4.19 | $98,465.00 | | |
| 6/4/2013 | Robert F Apple | CFO | Sell | 115,000 | $4.02 | $462,300.00 | | |
| 6/3/2013 | Anton Gueth | Director | Sell | 25,000 | $4.01 | $100,250.00 | | |
| 6/3/2013 | Kaushik J Dave | EVP | Sell | 48,000 | $4.01 | $192,480.00 | | |
| 6/3/2013 | Paul K Wotton | CEO | Sell | 125,000 | $4.01 | $501,250.00 | | |
| 5/31/2013 | Thomas J Garrity | Director | Sell | 13,000 | $4.08 | $53,040.00 | | |
| 5/17/2013 | Leonard S Jacob | Director | Sell | 17,000 | $4.00 | $68,000.00 | | |
| 11/16/2012 | Leonard S Jacob | Director | Buy | 10,000 | $3.44 | $34,400.00 | | |
(Data available from 1/1/2013 forward)
Antares Pharma (NASDAQ ATRS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Antares Pharma, Inc. (ATRS) Expected to Post Quarterly Sales of $14.44 Million
www.americanbankingnews.com - May 19 at 1:55 AM |
| Jacques Gonella Sells 200,000 Shares of Antares Pharma, Inc. (ATRS) Stock
www.americanbankingnews.com - May 18 at 7:39 PM |
| Analysts Anticipate Antares Pharma, Inc. (ATRS) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 17 at 11:15 PM |
| Antares Pharma, Inc. (ATRS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 17 at 1:39 AM |
| Antares Pharma, Inc. (ATRS) Director Sells $500,000.00 in Stock
www.americanbankingnews.com - May 16 at 7:52 PM |
 | Form 4 ANTARES PHARMA, INC. For: May 10 Filed by: GONELLA JACQUES
www.streetinsider.com - May 15 at 8:19 AM |
| Antares Pharma, Inc. (ATRS) Director Sells $484,000.00 in Stock
www.americanbankingnews.com - May 14 at 7:40 PM |
 | ATRS: Makena Maturing Quickly, Providing 1Q:18 Boost
finance.yahoo.com - May 14 at 5:25 PM |
| Antares Pharma, Inc. (ATRS) to Post FY2018 Earnings of ($0.09) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - May 14 at 3:49 AM |
| Form 4 ANTARES PHARMA, INC. For: May 09 Filed by: GONELLA JACQUES
www.streetinsider.com - May 12 at 6:03 PM |
| Antares Pharma, Inc. (ATRS) Director Jacques Gonella Sells 300,000 Shares
www.americanbankingnews.com - May 11 at 7:41 PM |
| Antares Pharma, Inc. (ATRS) Expected to Post FY2018 Earnings of ($0.05) Per Share
www.americanbankingnews.com - May 11 at 11:04 AM |
| Brokers Issue Forecasts for Antares Pharma, Inc.'s Q2 2018 Earnings (ATRS)
www.americanbankingnews.com - May 11 at 9:31 AM |
| Equities Analysts Set Expectations for Antares Pharma, Inc.'s Q2 2018 Earnings (ATRS)
www.americanbankingnews.com - May 11 at 9:31 AM |
| Antares Pharma (ATRS) Issues Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 5:30 PM |
| Edited Transcript of ATRS earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:18 AM |
| Piper Jaffray Research Analysts Lower Earnings Estimates for Antares Pharma, Inc. (ATRS)
www.americanbankingnews.com - May 10 at 7:55 AM |
| Form 4 ANTARES PHARMA, INC. For: May 03 Filed by: GONELLA JACQUES
www.streetinsider.com - May 9 at 8:13 AM |
 | BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04
www.reuters.com - May 9 at 8:13 AM |
 | Antares Pharma's (ATRS) CEO Robert Apple on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:46 PM |
| Antares Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:46 PM |
| Antares Pharma (ATRS) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - May 8 at 3:28 PM |
| Antares Pharma misses by $0.01, misses on revenue
seekingalpha.com - May 8 at 8:10 AM |
| Antares Pharma Reports First Quarter 2018 Operating and Financial Results
finance.yahoo.com - May 8 at 8:10 AM |
| Jefferies Group Brokers Increase Earnings Estimates for Antares Pharma, Inc. (ATRS)
www.americanbankingnews.com - May 4 at 5:49 AM |
| Antares Pharma (ATRS) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM |
| Analysts Issue Forecasts for Antares Pharma, Inc.'s Q4 2018 Earnings (ATRS)
www.americanbankingnews.com - May 3 at 9:30 AM |
| Antares Pharma to Present at the Deutsche Bank Securities, Inc. 43rd Annual Health Care Conference
finance.yahoo.com - May 2 at 8:16 AM |
| $13.45 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter
www.americanbankingnews.com - May 2 at 3:54 AM |
| Antares Pharma (ATRS) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 1 at 9:12 AM |
| Antares Pharma to Report First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 1 at 8:16 AM |
| -$0.03 Earnings Per Share Expected for Antares Pharma, Inc. (ATRS) This Quarter
www.americanbankingnews.com - April 30 at 11:20 AM |
| Antares Pharma Inc (ATRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 22 at 1:36 AM |
| Reviewing Antares Pharma (ATRS) and Interpace Diagnostics Gr (IDXG)
www.americanbankingnews.com - April 18 at 11:14 AM |
| Antares Pharma (ATRS) Raised to "Buy" at Vetr
www.americanbankingnews.com - April 17 at 4:47 PM |
| Antares Pharma (ATRS) Stock Rating Upgraded by Vetr
www.americanbankingnews.com - April 16 at 11:29 PM |
| Piper Jaffray Analysts Give Antares Pharma (ATRS) a $4.00 Price Target
www.americanbankingnews.com - April 15 at 11:43 PM |
| Brokerages Anticipate Antares Pharma Inc (ATRS) Will Announce Quarterly Sales of $13.45 Million
www.americanbankingnews.com - April 15 at 4:05 AM |
| Zacks: Brokerages Expect Antares Pharma Inc (ATRS) Will Announce Earnings of -$0.03 Per Share
www.americanbankingnews.com - April 13 at 11:34 AM |
| Antares Pharma (ATRS) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 13 at 10:01 AM |
| Antares Pharma (ATRS) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 11 at 11:52 PM |
| 3 Things In Biotech, April 7: Lilly's Surprising Liver Data, Antares's Retry Is Go, EyeGate Looks Toward The Future
seekingalpha.com - April 8 at 9:25 AM |
| Antares Pharma (ATRS) Downgraded by BidaskClub
www.americanbankingnews.com - April 5 at 10:26 AM |
| FDA accepts Antares Pharma's resubmitted Xyosted marketing application, action date September 29; shares up 10% premarket
seekingalpha.com - April 5 at 10:02 AM |
| Antares Pharma (ATRS) Says Complete Response Resubmission Accepted by FDA; PDUFA Date Set for September 29
www.streetinsider.com - April 5 at 10:02 AM |
| BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update
www.reuters.com - March 29 at 8:19 AM |
| Antares Pharma (ATRS) Receves Minutes from Type A Meeting with FDA in Connection with XYOSTED NDA
www.streetinsider.com - March 29 at 8:19 AM |
| $13.45 Million in Sales Expected for Antares Pharma Inc (ATRS) This Quarter
www.americanbankingnews.com - March 29 at 5:52 AM |
| Antares Pharma Inc (ATRS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 28 at 1:38 AM |
| ATRS: Xyosted Regulatory Update
finance.yahoo.com - March 27 at 5:19 PM |
Antares Pharma (NASDAQ:ATRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Antares Pharma (NASDAQ:ATRS) Income Statement, Balance Sheet and Cash Flow Statement
Antares Pharma (NASDAQ ATRS) Stock Chart for Monday, May, 21, 2018
Loading chart…
